The hypocretin/orexin system

Journal of the Royal Society of Medicine

Volumn 95, Issue 5, 2002, Pages 227-230

  Ebrahim, I O ^a   Howard, R S ^a   Kopelman, M D ^a   Sharief, M K ^a   Williams, A J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; OREXIN;

CEREBROSPINAL FLUID EXAMINATION; HUMAN; MENTAL DISEASE; NARCOLEPSY; NERVE PROJECTION; NEUROCHEMISTRY; NEUROENDOCRINE SYSTEM; NEUROLOGIC DISEASE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW;

EID: 0036097055     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.95.5.227     Document Type: Review

References (52)

1. The hypocretins: Excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding
2. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity
3. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G-protein coupled receptors that regulate feeding behaviour
4. Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction
5. Distribution of immunoreactive neurons and fibers for a hypothalamic neuropeptide precursor related to secretin
6. Two novel hypothalamic peptides related to secretin derived from a single neuropeptide precursor
7. The hypocretin/orexin ligand-receptor system: Implications for sleep and sleep disorders
8. Distribution of orexin receptor mRNA in the rat brain
9. The sandman's secrets
10. Perspectives in narcolepsy and hypocretin (orexin) research
11. Neurones containing hypocretin (orexin) project to multiple neuronal systems
12. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains
13. Reduced number of hypocretin neurons in human narcolepsy
14. Hypothalamic hypocretin (orexin): Robust innervation of the spinal cord
15. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system
16. Both corticotrophin releasing factor and neuropeptide Y are involved in the effect of orexin (hypocretin) on the food intake in rats
17. Presynaptic and postsynaptic actions and modulation of neuroendocrine neurones by a new hypothalamic peptide, hypocretin/orexin
18. Hypocretin-1 (orexin-A) produced changes in glutamate and GABA release: An in vivo microdialysis study
19. The effect of orexins on food intake: Comparison with neuropeptide Y, melanin-concentrating hormone and galanin
20. Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat
21. Neurons containing orexin in the lateral hypothalamic area of the adult rat brain are activated by insulin-induced acute hypoglycemia
22. Centrally administered orexin-hypocretin activates HPA axis in rats
23. Orexin synthesis and response in the gut
24. Cardiovascular regulatory actions of the hypocretins in brain
25. Effect of lateral cerebroventricular injection of the appetite-stimulating neuropeptides, orexin and neuropeptide Y, on the various behavioural activities of rats
26. Metabolic characterisation of orexin knockout mice
27. The hypocretin/orexin story
28. Narcolepsy: New understanding of irresistible sleep
29. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene
30. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation
31. Behavioural and polysomnographic characterization of orexin-1 receptor and orexin-2 receptor double knockout mice
32. The role of orexin receptor type-1 (OX1R) in the regulation of sleep
33. Behavioural characterisation of orexin-2 receptor (OX2R) knockout mice
34. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs
35. Hypocretin (orexin) deficiency in human narcolepsy
36. Hypocretin (orexin) levels in human lumbar CSF in different age groups
37. CSF hypocretin levels in various neurological conditions: Low levels in narcolepsy and Guillain Barré Syndrome
38. Hypocretin/orexin concentrations are low in patients with Guillain Barré syndrome
39. Monoamine dysfunction and the pathophysiology and treatment of depression
40. Narcolepsy: A neurodegenerative disease of the hypocretin system?
41. Noradrenaline in depressive reactions. A review
42. The biochemistry of affective disorders
43. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression
44. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor
45. Responses to corticotropin-releasing hormone in the hypercorticolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications
46. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression
47. Distinct mechanism for antidepressant activity by blockade of central substance P receptors
48. Research and treatment approaches to depression
49. Effects of high-affinity corticotropin releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated
50. Hypocretin deficiency in familial symptomatic narcolepsy
51. The role of the hypothalamic neuropeptides hypocretin/orexin the sleep-wake cycle
52. Hypothalamic arousal regions are activated during Modafinil-induced wakefulness